ArticleBioactive materials2025
Transdermal delivery of PeptiCRAd cancer vaccine using microneedle patches.
Article in Bioactive materials, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed.
- Advances in delivery technologies-powered cancer vaccines.Bioactive materials · 2026Review
- Microneedle-Assisted Delivery of Biologics: From Large Molecules to Cancer Vaccines.AAPS PharmSciTech · 2026Review
- Functionalized Polymeric Microneedles for Transdermal Delivery of Ovalbumin Protein Antigen.Pharmaceutics · 2025Article
- Clinical Translation Challenges and Strategies for Tumour Vaccines Considering Multiple Delivery Routes.Vaccines · 2025Review
- Beyond the Needle: Innovative Microneedle-Based Transdermal Vaccination.Medicines (Basel, Switzerland) · 2025Review
- Microneedles in biomedicine: Innovations, challenges, and future prospects.Biomaterials translational · 2025Review
- Enhancing melanoma therapy with hydrogel microneedles.Frontiers in oncology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Microneedles (MNs) are a prospective system in cancer immunotherapy to overcome barriers regarding proper antigen delivery and presentation. This study aims at identifying the potential of MNs for the delivery of Peptide-coated Conditionally Replicating Adenoviruses (PeptiCRAd), whereby peptides enhance the immunogenic properties of adenoviruses presenting tumor associated antigens. The combination of PeptiCRAd with MNs containing polyvinylpyrrolidone and sucrose was tested for the preservation of structure, induction of immune response, and tumor eradication. The findings indicated that MN-delivered PeptiCRAd was effective in peptide presentation
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.